Sri Sai Clinical Research Institute Profile
Key Indicators
- Authorised Capital ₹ 2.00 M
as on 04-07-2024
- Paid Up Capital ₹ 0.10 M
as on 04-07-2024
- Company Age 15 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Revenue %
(FY 2022)
- Ebitda
- Total Assets %
(FY 2022)
About Sri Sai Clinical Research Institute
The Company is engaged in the Education Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Kalarani Ganesan and Ganesan Munyandithevar serve as directors at the Company.
- CIN/LLPIN
U73100TN2009PTC070600
- Company No.
070600
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
29 Jan 2009
- Date of AGM
24 Oct 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Sri Sai Clinical Research Institute?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ganesan Munyandithevar  | Director | 29-Jan-2009 | Current |
| Kalarani Ganesan | Director | 29-Jan-2009 | Current |
Financial Performance of Sri Sai Clinical Research Institute.
Sri Sai Clinical Research Institute Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Sri Sai Clinical Research Institute?
In 2022, Sri Sai Clinical Research Institute had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Luminol Biopharma Private LimitedActive 7 years 7 monthsKalarani Ganesan and Ganesan Munyandithevar are mutual person
Micro Therapeutic Research Labs Private LimitedActive 19 years 10 monthsKalarani Ganesan and Ganesan Munyandithevar are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Sri Sai Clinical Research Institute?
Unlock and access historical data on people associated with Sri Sai Clinical Research Institute, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sri Sai Clinical Research Institute, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sri Sai Clinical Research Institute's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
